Reactive Arthritis vs Psoriatic Arthritis: Treatment Differences

Reactive arthritis and psoriatic arthritis can both cause swollen, painful joints — but they have different triggers, different long-term outlooks, and importantly, different treatment approaches. Reactive arthritis is typically triggered by an infection, tends to resolve on its own within a few months, and rarely requires long-term biologic drugs. Psoriatic arthritis is a chronic, lifelong condition linked to the immune system that almost always requires ongoing treatment and often benefits from targeted biologic therapies approved specifically for it.

This explainer draws on peer-reviewed research from four rheumatologists listed in the Convene directory whose published work shapes how both conditions are treated today: Christopher Ritchlin, MD, at the University of Rochester, who co-authored the 2018 ACR/NPF psoriatic arthritis treatment guideline and a landmark New England Journal of Medicine overview of PsA [1][2]; Arthur Kavanaugh, MD, at UC San Diego, who co-authored the GRAPPA international treatment recommendations and multiple pivotal biologic trials [3][4][5]; Norman Gaylis, MD, in Aventura, Florida, who published on anti-TNF therapy in Reiter's syndrome (an older name for reactive arthritis) including in patients with HIV [6][7]; and M. Elaine Husni, MD, at the Cleveland Clinic, whose work on PsA screening tools and psychosocial burden has informed how early diagnosis is approached [8][9].

What are these two conditions?

Reactive arthritis is inflammation of the joints that develops after an infection somewhere else in the body — usually the gut (from bacteria like Salmonella, Shigella, or Campylobacter) or the urogenital tract (often Chlamydia trachomatis). The immune system mounts a response to the infection, and in some people, that response mistakenly attacks the joints. The old term "Reiter's syndrome" referred to a classic triad of arthritis, urethritis, and eye inflammation; rheumatologists now prefer the broader label "reactive arthritis" because many patients do not have all three features.

Psoriatic arthritis is a chronic inflammatory condition that develops in roughly 20 to 30% of people with psoriasis — the skin condition that causes thick, scaly patches. Some people develop joint symptoms before their skin disease becomes obvious, which can delay diagnosis. Psoriatic arthritis can affect peripheral joints (fingers, wrists, knees), the spine, tendon attachment points (entheses), and the whole finger or toe in a pattern called dactylitis, giving affected digits a sausage-like swelling. Unlike reactive arthritis, it does not have an infectious trigger and does not go away on its own [1].

How each is diagnosed

There is no single blood test that confirms either condition. Diagnosis relies on the clinical picture, imaging, and ruling out other causes.

For reactive arthritis, the key clue is the timeline: joint swelling that starts within one to four weeks of a gastrointestinal or urogenital infection, in a relatively young patient, affecting large lower-extremity joints (especially the knee and ankle) asymmetrically. HLA-B27, a genetic marker, is present in about 50 to 80% of patients with reactive arthritis and is associated with more severe or prolonged disease, but it is not required for diagnosis.

For psoriatic arthritis, the 2007 CASPAR criteria are the standard: a doctor scores points for the presence of psoriasis (current skin or nail disease, or family history), psoriatic nail changes, a negative rheumatoid factor, dactylitis, and new bone formation on X-ray. A total of three or more points in a patient with inflammatory joint disease confirms the diagnosis. Because patients often see dermatologists before rheumatologists, early detection tools like the Psoriatic Arthritis Screening and Evaluation (PASE) questionnaire — piloted by Husni and colleagues — help identify people with psoriasis who may be developing joint involvement and need a rheumatology referral [8].

At a glance

Treating reactive arthritis

For most people with reactive arthritis, treatment is straightforward: rest the joint, use a nonsteroidal anti-inflammatory drug (NSAID) like naproxen or indomethacin to reduce pain and swelling, and wait. The majority of cases resolve within three to six months.

If an active bacterial infection is still present (particularly with Chlamydia trachomatis), the infection itself needs antibiotic treatment — though antibiotics do not shorten the joint inflammation once it has started. Corticosteroid injections directly into an inflamed joint can help in the short term when one or two joints are severely affected.

A minority of patients develop persistent or recurrent disease. In these cases, rheumatologists may use conventional disease-modifying antirheumatic drugs (DMARDs) like sulfasalazine or methotrexate, following a similar rationale to their use in other inflammatory arthropathies. Anti-TNF biologics have been used in refractory cases, including in a particularly challenging setting: HIV-positive patients with severe reactive arthritis who do not respond to NSAIDs. Gaylis published a case report and follow-up on an HIV-positive patient with Reiter's syndrome treated with infliximab — reporting sustained improvement in joint symptoms over years with careful infectious disease monitoring [6][7]. This work helped establish that TNF inhibition can be used cautiously in reactive arthritis patients with concurrent HIV when other treatments have failed.

Treating psoriatic arthritis

Psoriatic arthritis requires long-term management because the inflammation does not stop on its own. The 2018 ACR/NPF guideline, co-developed by Ritchlin and colleagues, established a practical framework for treatment decision-making across common clinical scenarios [2].

For mild disease affecting only a few peripheral joints, NSAIDs are often tried first. When they are insufficient, conventional DMARDs — methotrexate, sulfasalazine, leflunomide — are the traditional next step, particularly when psoriasis is also active.

For moderate to severe disease, or when the spine, entheses, or many joints are involved, biologic therapies have transformed outcomes. TNF inhibitors (adalimumab, etanercept, infliximab, certolizumab, golimumab) were the first class approved for PsA and remain widely used. Two more recent drug classes have added important options:

IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab) target a different inflammatory pathway and are particularly effective for psoriasis skin disease alongside joint symptoms. Kavanaugh was a co-investigator on the FUTURE 2 phase 3 trial of secukinumab in PsA, published in The Lancet, which showed significant improvements in ACR response rates, physical function, and quality of life compared to placebo [3].

IL-12/23 and IL-23 inhibitors (ustekinumab, guselkumab, risankizumab) take yet another approach. Kavanaugh led the PSUMMIT 1 trial of ustekinumab in PsA, published in The Lancet, demonstrating efficacy in patients with active disease — including those who had previously failed anti-TNF therapy, which is a common clinical challenge [4].

The 2021 GRAPPA updated treatment recommendations, which Kavanaugh co-authored, reflect how much the treatment landscape has evolved: rheumatologists now have multiple biologic options across five distinct drug classes, and the choice depends on factors like skin disease severity, presence of axial involvement, prior treatment history, and comorbidities [5].

The psychosocial side of psoriatic arthritis

Reactive arthritis, when it resolves in a few months, has a limited impact on a person's long-term life. Psoriatic arthritis is different. Because it is chronic and affects visible features (skin and joints), the psychological toll is substantial and often underappreciated.

Husni and colleagues examined this burden directly in a 2017 review published in Seminars in Arthritis and Rheumatism [9]. Patients with PsA report high rates of anxiety and depression, reduced social participation, and impaired work productivity — often exceeding what would be predicted from their joint counts alone. Fatigue is a persistent complaint that standard disease activity measures do not fully capture. This means treatment goals need to extend beyond X-ray scores and joint counts: managing the psychological and functional impact of disease is part of good care.

When to see a rheumatologist

For reactive arthritis: if your joint symptoms started shortly after a gastrointestinal or urogenital illness and have not improved after four to six weeks of NSAIDs, a rheumatologist can confirm the diagnosis, rule out other causes, and guide next steps.

For psoriatic arthritis: if you have psoriasis and notice new joint pain, stiffness, swelling, or nail changes, early referral matters. Research shows that joint damage in PsA can accumulate quickly in the first few years of disease, and earlier treatment is associated with better long-term outcomes. The PASE screening tool, developed with Husni's involvement, is specifically designed to help dermatologists and primary care doctors identify psoriasis patients who should be referred [8].

Questions to ask your rheumatologist

• Is this reactive arthritis or psoriatic arthritis? What makes you confident in that distinction?
• If it is reactive arthritis, what is my likelihood of full resolution, and at what point would you escalate treatment?
• If it is psoriatic arthritis, which joints and structures are currently affected — and do I have any early damage on imaging?
• Am I a candidate for a biologic? Which class would you recommend for my combination of skin and joint disease?
• What does "treat to target" mean for my case — what numbers or symptoms would indicate my disease is well controlled?
• Are there comorbidities (cardiovascular risk, inflammatory bowel disease, uveitis) that should factor into my treatment choice?

The bottom line

Reactive arthritis and psoriatic arthritis share a family resemblance — both fall under the spondyloarthritis umbrella — but they diverge sharply in treatment. Reactive arthritis is usually self-limiting and managed with NSAIDs; biologics are reserved for the minority with refractory disease. Psoriatic arthritis is a chronic condition with a growing toolkit of targeted biologic and small-molecule therapies — including TNF inhibitors, IL-17 inhibitors, and IL-23 inhibitors — that have changed what is possible for patients when treated early and aggressively enough.